Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Caliway Biopharmaceuticals Co's EV-to-OCF or its related term are showing as below:
TPE:6919'
s EV-to-OCF Range Over the Past 10 Years
Min: -845.01 Med: -230.17 Max: -68.15
Current: -537.63
During the past 7 years, the highest EV-to-OCF of Caliway Biopharmaceuticals Co was -68.15. The lowest was -845.01. And the median was -230.17.
TPE:6919's EV-to-OCF is ranked better than 99.15% of 1408
companies
in the Biotechnology industry
Industry Median: -3.72
vs TPE:6919: -537.63
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Caliway Biopharmaceuticals Co (TPE:6919) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Caliway Biopharmaceuticals Co's PE Ratio (TTM) for today is calculated as:
Caliway Biopharmaceuticals Co's share price for today is NT$99.60.
Caliway Biopharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Caliway Biopharmaceuticals Co EV-to-OCF Related Terms
Caliway Biopharmaceuticals Co EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6919 vs VRTX, REGN, MRNA: EV-to-OCF Comparison
For the Biotechnology subindustry, Caliway Biopharmaceuticals Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caliway Biopharmaceuticals Co EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caliway Biopharmaceuticals Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Caliway Biopharmaceuticals Co's EV-to-OCF falls into.
Caliway Biopharmaceuticals Co's current Enterprise Value is NT$151,068.30 Mil.
Caliway Biopharmaceuticals Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-280.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caliway Biopharmaceuticals Co (TPE:6919) has a EV-to-OCF of -537.63 as of Aug. 31, 2026. According to the industry distribution chart, Caliway Biopharmaceuticals Co ranks #12 out of 1408 companies in the Biotechnology industry, placing it in the top 0.90000000000001%.
Is Caliway Biopharmaceuticals Co's EV-to-OCF too high?
Caliway Biopharmaceuticals Co's current EV-to-OCF is -537.63. Based on the distribution chart, Caliway Biopharmaceuticals Co ranks #12 out of 1408 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Caliway Biopharmaceuticals Co has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caliway Biopharmaceuticals Co's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Caliway Biopharmaceuticals Co ranks #12 out of 1408 companies for EV-to-OCF. This places Caliway Biopharmaceuticals Co in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Caliway Biopharmaceuticals Co's current EV-to-OCF is -537.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caliway Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co (TPE:6919) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$59.00, compared to a current price of NT$99.60 — trading 68.8% above its estimated fair value. The current EV-to-OCF is -537.63. Caliway Biopharmaceuticals Co's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Caliway Biopharmaceuticals Co (TPE:6919), the current EV-to-OCF is -537.63 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caliway Biopharmaceuticals Co (TPE:6919) Overvalued in 2026?
Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of NT$99.60 is trading 68.8% above its estimated GF Value™ of NT$59.00.
GuruFocus considers Caliway Biopharmaceuticals Co to be Significantly Overvalued.
Key valuation signals for TPE:6919:
EV-to-OCF: -537.63
GF Value™: NT$59.00 vs. price of NT$99.60 (68.8% above fair value)
No single metric tells the full story. See the TPE:6919 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caliway Biopharmaceuticals Co Ltd specializes in the development of new drugs for aesthetic medicine and chronic inflammation. The group has one operating segment, which is Healthy Food, and others.
55GF Score
Get the complete analysis for TPE:6919
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6919 has been successfully added to your 
